Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC grew its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 18.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,192 shares of the company’s stock after buying an additional 1,888 shares during the period. Los Angeles Capital Management LLC’s holdings in Twist Bioscience were worth $551,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Sei Investments Co. grew its stake in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after acquiring an additional 55,124 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in shares of Twist Bioscience by 38.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Twist Bioscience by 210.2% in the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after purchasing an additional 83,287 shares during the last quarter. Magnetar Financial LLC purchased a new position in Twist Bioscience during the first quarter worth approximately $389,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock worth $1,103,000 after buying an additional 2,292 shares during the last quarter.

Twist Bioscience Stock Down 5.3 %

Shares of NASDAQ TWST opened at $36.89 on Friday. The business’s 50 day moving average is $43.90 and its two-hundred day moving average is $46.02. Twist Bioscience Co. has a 52-week low of $18.80 and a 52-week high of $60.90. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -9.66 and a beta of 1.78.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $639,296.40. Following the completion of the transaction, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. The trade was a 2.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 856 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares in the company, valued at approximately $3,068,728.57. This trade represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent research reports. Barclays cut their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Evercore ISI lifted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. increased their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.